Biomarker and Genetic Predictors of Erenumab Treatment Response (INTERROGATE)

NCT04265755 PHASE4 COMPLETED Results posted

To explore the relationship between clinical response to erenumab and genetic biomarkers

Details

Lead sponsor	Amgen
Phase	PHASE4
Status	COMPLETED
Enrolment	1406
Start date	Mon Oct 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Migraine

Interventions

• Erenumab

Countries

Denmark, Iceland